[1］ Amgen Inc. VectibixTM(Panitumumab).[EB/OL] Amgen Inc. [2007-10] www.amgen.com/pdfs/misc/vectibix-pi.pdf. [2］ HECHT J，MITCHELL E，BARANDA J，et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1%～9%) or negative (less than 1%) levels of epidermal growth factor receptor (EGFr)[J］. Proc Am Soc Clin Oncol，2006，24(18S)：3547. [3］ MALIK I，HECHT J R，PATNAIK A，et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC) [J］. Proc Am Soc Clin Oncol，2005，23(16S)：3520. [4］ MEROPOL N J，BERLIN J，HECHT J R，et al. Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer[J］. Proc Am Soc Clin Oncol，2003，22：1026. [5］ ROWINSKY E K，SCHWARTZ G H，GOLLOB J A，et al. Safety，pharmacokinetics，and activity of ABX-EGF，a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer[J］. J Clin Oncol，2004，22(15)：3003-3015. [6］ FIGLIN R A，BELLDEGRUN A S，CRAWFORD J，et al. ABX-EGF，a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer： phase 1 clinical results [J］. Proc Am Soc Clin Oncol，2002，21：35. [7］ CRAWFORD J，SANDLER A B，HAMMOND L A，et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC) [J］. Proc Am Soc Clin Oncol，2004，22(14S)：7083. [8］ BERLIN J，NEUBAUER M，SWANSON P，et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing at least 10% epidermal growth factor receptor (EGFr) [J］. Proc Am Soc Clin Oncol，2006，24(18S)：3548. [9］ HECHT J，POSEY J，TCHEKMEDYIAN S，et al. Panitumumab in combination with 5-fluorouracil，leucovorin，and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC) [J］. Proc Am Soc GI Symp，2006：237.